Clinical trial

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

NCT06138600

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Cabotegravir Injection [Apretude] Normalized identity: cabotegravir Injection [Apretude]View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tenofovir disoproxil fumarate / emtricitabine (or lamivudine) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-11-01

PhasePHASE3

Conditions

HIV Infectionsunresolved

Interventions

Cabotegravir Injection [Apretude]DRUG · verified · RxNorm: cabotegravir Injection [Apretude]

Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)DRUG

Sponsors & collaborators

University of Witwatersrand, South Africalead sponsor

ViiV Healthcarecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06138600 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.